论文部分内容阅读
八十年代曾有人报道,甲状旁腺相关蛋白(PTHrP)是引起恶性肿瘤致体液性高血钙(Humoralhypercalcemia of malignancy,HHM)的原因标志物。健康人血清中PTHrP浓度极低或测不到,但在实体性肿瘤或引起HHM的肿瘤患者则明显升高。九十年代以来,人们发现PTHrP与很多实体性恶性肿瘤的发生、发展有着密切的关系。有报道73％的乳腺癌,64％泌尿生殖系恶性肿瘤和46％的肺癌患者血清中PTHrP明显升高。我们从1996年10月～1998年4月应用放射免疫分析法(RIA)和免疫放射分析法(IRMA)对31例前列腺癌患者进行了PSA和PTHrP的联合检测,并观察了其中12例前列腺癌患者治疗前及治疗后18个月PSA和PTHrP的含量变化。现将结果报告如下。
In the 1980s, it was reported that parathyroid hormone-related protein (PTHrP) is a causative marker of humoral hypercalcemia of malignancy (HHM) caused by malignant tumors. The concentration of PTHrP in healthy human serum was extremely low or undetectable, but it was significantly higher in patients with solid tumors or HHM-induced tumors. Since the 1990s, it has been found that PTHrP is closely related to the occurrence and development of many solid malignant tumors. It has been reported that 73% of breast cancer, 64% of urogenital malignancies and 46% of lung cancer patients PTHrP significantly increased serum. We performed radioimmunoassay (RIA) and immunoradiometric assay (IRMA) from January 1996 to April 1998 on 31 patients with prostate cancer who underwent combined detection of PSA and PTHrP and observed 12 of them. Changes in PSA and PTHrP levels before and after treatment in patients. The results reported below.